ASSAY FOR ANTIBACTERIALS AFFECTING INITIATION FACTOR 3

Information

  • Research Project
  • 2777508
  • ApplicationId
    2777508
  • Core Project Number
    R43AI044523
  • Full Project Number
    1R43AI044523-01
  • Serial Number
    44523
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1999 - 26 years ago
  • Project End Date
    2/29/2000 - 25 years ago
  • Program Officer Name
    TSENG, CHRISTOPHER K.
  • Budget Start Date
    9/1/1999 - 26 years ago
  • Budget End Date
    2/29/2000 - 25 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/18/1999 - 26 years ago
Organizations

ASSAY FOR ANTIBACTERIALS AFFECTING INITIATION FACTOR 3

New antibiotics are desperately needed as clinically significant bacterial pathogens have acquired resistance to nearly all existing antibiotics. We describe a high-throughput screening system for identifying new antibacterial agents specifically targeted against an integral component of the bacterial translation apparatus. Work described in this application will identify compounds that selectively inhibit the bacterial initiation factor IF3. We propose to implement a primary screening assay to identify inhibitors of E. coli IF3. The assay uses a reporter fusion system in whole cells and is a parodoxical growth assay. Inhibitors of IF3 are expected to result in increased growth of cells due to higher levels of expression from the reporter gene. Following the primary assay a series of in vitro secondary assays designed to confirm that inhibitors target IF3 function will be performed. Reporter constructs analogous to those used in the primary screening assay will be used in in vitro translation reactions to determine the exact nature of IF3 inhibition. Finally, positive compounds will be evaluated for antibacterial efficacy and for toxicity in mammalian cells. PROPOSED COMMERCIAL APPLICATIONS: This research will develop a new assay to identify novel antibacterial drugs for treating bacterial. infections.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG5
  • Study Section Name
  • Organization Name
    RIBOGENE, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    HAYWARD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94545
  • Organization District
    UNITED STATES